Positive Safety and Efficacy Data Move Off-the-Shelf CAR-T into Registry Trial

CRISPR Therapeutics’ off-the-shelf CAR-T treatment conferred clinical benefits similar to those achieved with CAR-T treatments derived from the patients’ own cells, posting a 58 percent overall response and 38 percent complete response rate in a small series of patients with large B-cell lymphoma.

Buoyed by these and excellent safety results, the company announced that it will advance CTX110 into a registry trial early next year. Registry studies are observational as they look at what was done without dictating a treatment.

“We think we have not just a first-in-class, but best-in-class allogenic therapy and we want to focus on getting this into clinical settings,” said CRISPR Therapeutics’ CEO Samarth Kulkarni.